Mergers and acquisitions

#Biologics / Biotechnology #Cytiva #Mergers and acquisitions #Pall Life Sciences

Cytiva and Pall Life Sciences complete integration

Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. In January 2023, the life sciences business of Pall separated from Pall Corporation. Pall’s biotech portfolio is now a product family in Cytiva’s bioprocess business. The… Read More

#Business & Investment #News

Business acquisition
#Mergers and acquisitions #Rare disease #Rhythm Pharmaeuticals #Xinvento

Rhythm Pharmaceuticals buys biotech focused on rare disease

Biopharmaceutical subsidiary Rhythm Pharmaceuticals Netherlands has acquired Xinvento, a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).  CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death.   Xinvento… Read More

#Business & Investment #News

#Bioanalytics #Cell and gene therapy #Mergers and acquisitions #Waters Corporation

Waters acquires bioanalytics company Wyatt Technology

Waters Corporation has revealed it will acquire Wyatt Technology, a provider of light scattering and field-flow fractionation instruments, software, accessories, and services, for $1.36 billion.  The transaction is expected to close in the second quarter of 2023, subject to regulatory approvals and other closing conditions. … Read More

#News

Businesswomen shaking hands
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Envision Pharma #Life sciences #Mergers and acquisitions #OKRA.ai

Envision Pharma Group acquires OKRA.ai

Envision Pharma Group has acquired OKRA.ai, a provider of artificial intelligence (AI) services for the pharmaceutical and life sciences industry. “We are delighted to welcome OKRA.ai into the Envision family,” said Meg Heim, CEO, Envision Pharma Group. “The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence… Read More

#Business & Investment #News

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

Catch up with the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Once again, research partnerships and licence agreements have dominated the news… Read More

#News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

This week in drug discovery (9-13 January)

News round-up for 9-13 January by DDW Digital Content Editor Diana Spencer. Once again, research partnerships and licence agreements have dominated the news this week, as drug discovery companies seek new ways to combine their expertise to address unmet medical needs.  The top stories: … Read More

#News

Respiratory system
#Cambrian BioPharma #Idiopathic pulmonary fibrosis #Isterian Biotech #Mergers and acquisitions

Cambrian expands fibrosis pipeline

Cambrian BioPharma has unveiled its latest pipeline company, Isterian Biotech.   The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases.  With age a… Read More

#Business & Investment #News

Patient checking own blood pressure
#Acquisition #AstraZeneca #Chronic kidney disease (CKD) #Hypertension #Mergers and acquisitions

AstraZeneca gains rights to novel aldosterone synthase inhibitor

AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.  As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood… Read More

#Business & Investment #Editor's Choice #News

#Acquisition #AmerisourceBergen #Drug discovery #Mergers and acquisitions #Pharma services #PharmaLex

AmerisourceBergen completes acquisition of PharmaLex

AmerisourceBergen Corporation has completed its acquisition of PharmaLex Holding, a provider of tech-enabled services from clinical development consulting to marketing authorisation.  PharmaLex is a global team of scientific, regulatory and safety and compliance (GxP) experts that provide strategic guidance and regulatory support to biopharma companies throughout a product’s lifecycle.  The… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

Mouse in laboratory
#Avista #Mergers and acquisitions #Pharma services #Taconic

Avista continues investment in pharma services with Taconic acquisition 

Avista Capital Partners has acquired Taconic Biosciences, a provider of genetically engineered research models (GEMs), as it reaches its 70th anniversary.  Taconic specialises in genetically engineered research models and services, specifically murine models for use in drug discovery research and non-clinical safety testing.  The company has reassured customers that there… Read More

#Business & Investment #News

#Citeline #Clinical trials #Mergers and acquisitions #Norstella #Pharma intelligence

Merger creates $5 billion pharma technology company 

Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market.  Norstella now has more than 1,500 employees across its five brands: Evaluate, MMIT, Panalgo, The Dedham Group, and Citeline.  “We believe that patient access starts… Read More

#Business & Investment #News

Antibodies attacking cancer cell
#Bispecific Antibodies #Cancer research #Cancer treatment #Mergers and acquisitions #Monoclonal antibodies #Oncology

Jazz acquires rights to HER2-targeted bispecific antibody

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. Zymeworks will receive a $50 million upfront payment, a second payment of $325 million, at Jazz’s option, and further potential… Read More

#Cancer Research #News

Microbiome
#Bioinformatics #Gut microbiome #Mergers and acquisitions #Metabolomics #Microbiome

Acquisition will “integrate microbiome and metabolome data”

Microbiome research company Clinical Microbiomics has acquired MS-Omics, a leading provider based in Denmark.   With this acquisition, Clinical Microbiomics hopes to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.    Anders Grøn, CEO at Clinical Microbiomics, commented: “There is… Read More

#Business & Investment #News

#Acquisition #Biorepository #Biospecimen collection #Mergers and acquisitions

BioIVT expands into new therapy areas with Fidelis acquisition

BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe.  Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs).  “This transaction increases BioIVT’s global operations by adding new clinical collection sites, which… Read More

#News